AI assistant
Cabaletta Bio, Inc. — Director's Dealing 2022
Feb 2, 2022
33628_dirs_2022-02-02_5fcd7494-9291-4e24-af2e-39c8e2988d53.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cabaletta Bio, Inc. (CABA)
CIK: 0001759138
Period of Report: 2022-01-31
Reporting Person: Nichtberger Steven (Director, President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-01-31 | Common Stock | M | 50000 | $1.01 | Acquired | 836483 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-31 | Stock Option (Right to Buy) | $1.01 | M | 50000 | Disposed | 2028-10-28 | Common Stock (50000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 363000 | Indirect |
Footnotes
F1: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2: On October 29, 2018, the reporting person was granted a stock option to purchase 279,677 shares of common stock. The shares vest and become exercisable over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 36 equal monthly installments thereafter. On January 31, 2022 the reporting person exercised this option for 50,000 shares.